292 related articles for article (PubMed ID: 11986128)
1. Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders.
Strauss WL; Unis AS; Cowan C; Dawson G; Dager SR
Am J Psychiatry; 2002 May; 159(5):755-60. PubMed ID: 11986128
[TBL] [Abstract][Full Text] [Related]
2. 19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder.
Strauss WL; Layton ME; Hayes CE; Dager SR
Am J Psychiatry; 1997 Apr; 154(4):516-22. PubMed ID: 9090339
[TBL] [Abstract][Full Text] [Related]
3. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy.
Bolo NR; Hodé Y; Nédélec JF; Lainé E; Wagner G; Macher JP
Neuropsychopharmacology; 2000 Oct; 23(4):428-38. PubMed ID: 10989270
[TBL] [Abstract][Full Text] [Related]
4. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Williams K; Brignell A; Randall M; Silove N; Hazell P
Cochrane Database Syst Rev; 2013 Aug; (8):CD004677. PubMed ID: 23959778
[TBL] [Abstract][Full Text] [Related]
5. Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.
Figgitt DP; McClellan KJ
Drugs; 2000 Oct; 60(4):925-54. PubMed ID: 11085201
[TBL] [Abstract][Full Text] [Related]
6. Long-term sequestration of fluorinated compounds in tissues after fluvoxamine or fluoxetine treatment: a fluorine magnetic resonance spectroscopy study in vivo.
Bolo NR; Hodé Y; Macher JP
MAGMA; 2004 May; 16(6):268-76. PubMed ID: 15042463
[TBL] [Abstract][Full Text] [Related]
7. The use of selective serotonin reuptake inhibitors in autism and related disorders.
Posey DJ; Erickson CA; Stigler KA; McDougle CJ
J Child Adolesc Psychopharmacol; 2006; 16(1-2):181-6. PubMed ID: 16553538
[TBL] [Abstract][Full Text] [Related]
8. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Williams K; Wheeler DM; Silove N; Hazell P
Cochrane Database Syst Rev; 2010 Aug; (8):CD004677. PubMed ID: 20687077
[TBL] [Abstract][Full Text] [Related]
9. A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder.
Dannon PN; Iancu I; Lowengrub K; Gonopolsky Y; Musin E; Grunhaus L; Kotler M
Clin Neuropharmacol; 2007; 30(6):326-34. PubMed ID: 18090457
[TBL] [Abstract][Full Text] [Related]
10. Serotonin reuptake inhibitor treatment of obsessive-compulsive symptoms in clozapine-medicated schizophrenia.
Andrade C
J Clin Psychiatry; 2012 Nov; 73(11):e1362-4. PubMed ID: 23218164
[No Abstract] [Full Text] [Related]
11. Fluvoxamine treatment of a child with severe PDD: a single case study.
Kauffmann C; Vance H; Pumariega AJ; Miller B
Psychiatry; 2001; 64(3):268-77. PubMed ID: 11708052
[TBL] [Abstract][Full Text] [Related]
12. Excretion of paroxetine into breast milk.
Ohman R; Hägg S; Carleborg L; Spigset O
J Clin Psychiatry; 1999 Aug; 60(8):519-23. PubMed ID: 10485633
[TBL] [Abstract][Full Text] [Related]
13. Maternal fluoxetine treatment in the postpartum period: effects on platelet serotonin and plasma drug levels in breastfeeding mother-infant pairs.
Epperson CN; Jatlow PI; Czarkowski K; Anderson GM
Pediatrics; 2003 Nov; 112(5):e425. PubMed ID: 14595087
[TBL] [Abstract][Full Text] [Related]
14. Plasma fluoxetine concentrations and clinical improvement in an adolescent sample diagnosed with major depressive disorder, obsessive-compulsive disorder, or generalized anxiety disorder.
Blázquez A; Mas S; Plana MT; Gassó P; Méndez I; Torra M; Arnaiz JA; Lafuente A; Lázaro L
J Clin Psychopharmacol; 2014 Jun; 34(3):318-26. PubMed ID: 24743718
[TBL] [Abstract][Full Text] [Related]
15. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
Preskorn SH
Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
[TBL] [Abstract][Full Text] [Related]
16. Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders.
Dinca O; Paul M; Spencer NJ
J Psychopharmacol; 2005 Sep; 19(5):521-32. PubMed ID: 16166190
[TBL] [Abstract][Full Text] [Related]
17. [The transfer of selective serotonin reuptake inhibitors to human milk].
Nordeng H; Bergsholm YK; Bøhler E; Spigset O
Tidsskr Nor Laegeforen; 2001 Jan; 121(2):199-203. PubMed ID: 11475200
[TBL] [Abstract][Full Text] [Related]
18. Psychopharmacology of comorbid obsessive-compulsive disorder and depression.
den Boer JA
J Clin Psychiatry; 1997; 58 Suppl 8():17-9. PubMed ID: 9236731
[TBL] [Abstract][Full Text] [Related]
19. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone.
Eap CB; Bertschy G; Powell K; Baumann P
J Clin Psychopharmacol; 1997 Apr; 17(2):113-7. PubMed ID: 10950475
[TBL] [Abstract][Full Text] [Related]
20. Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions.
Mandrioli R; Mercolini L; Saracino MA; Raggi MA
Curr Med Chem; 2012; 19(12):1846-63. PubMed ID: 22414078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
